Publications by authors named "David A Stock"

Claim this Profile
R
Rimegepant orally disintegrating tablet for acute treatment of migraine: a plain language summary of a clinical study.
Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw, Elyse G Stock

Pain Manag· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
Shengyuan Yu, Byung-Kun Kim, Aihong Guo, Man-Ho Kim, Mingjie Zhang, David A Stock

Lancet Neurol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
Richard B Lipton, Robert Croop, David A Stock, Jennifer Madonia, Micaela Forshaw

Lancet Neurol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Robert Croop, Jennifer Madonia, David A Stock, Alexandra Thiry, Micaela Forshaw

Headache· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
Rajinder Bhardwaj, Julie L Collins, Joseph Stringfellow, Jennifer Madonia, Matt S Anderson, David A Stock

Clin Pharmacol Drug Dev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of microbial analyses to feeds and potential implications for poultry nutrition.
Elena G Olson, Dana K Dittoe, Joshua A Jendza, David A Stock, Steven C Ricke

Poult Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women.
Teresa E Baker, Robert Croop, Lisa Kamen, Patty Price, David A Stock

Breastfeed Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Robert Croop, Richard B Lipton, David Kudrow, David A Stock, Lisa Kamen, Elyse G Stock

Lancet· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response.
Gilbert J L'Italien, Robert Croop, David A Stock

Headache· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing rimegepant for migraine-time to revise the trial design? - Authors' reply.
Robert Croop, Peter J Goadsby, David A Stock, Richard B Lipton

Lancet· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw, Elyse G Stock

Lancet· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Richard B Lipton, Robert Croop, Elyse G Stock, David A Stock, Beth A Morris

N Engl J Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Javier Morales-Ramirez, Johannes R Bogner, Jean-Michel Molina, Johan Lombaard, Ira B Dicker, David A Stock

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Melanie Thompson, Jacob P Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, David A Stock

Antivir Ther· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Max Lataillade, Nannan Zhou, Samit R Joshi, Sangil Lee, David A Stock

J Acquir Immune Defic Syndr· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Samir K Gupta, Grace A McComsey, John Lombaard, Juan Echevarría, Catherine Orrell, David A Stock

Lancet HIV· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Jacob P Lalezari, Gulam H Latiff, Cynthia Brinson, Juan Echevarría, Sandra Treviño-Pérez, David A Stock

Lancet HIV· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best practices in compound management for preserving compound integrity and accurately providing samples for assays.
Sandra L Matson, Moneesh Chatterjee, David A Stock, John E Leet, Elizabeth A Dumas

J Biomol Screen· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.
Sarah H Tannehill-Gregg, Mark A Dominick, Amy J Reisinger, Jeffrey D Moehlenkamp, C Robbie Waites, David A Stock

Toxicol Pathol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble Abeta and cognitive function in aged F-344 rats and Tg2576 mice.
Mark D Lindner, John B Hogan, Rudolph G Krause, Frederic Machet, Clotilde Bourin, David A Stock

Behav Brain Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An empirical process for the design of high-throughput screening deck filters.
Bradley C Pearce, Michael J Sofia, Andrew C Good, Dieter M Drexler, David A Stock

J Chem Inf Model· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
Mark D Lindner, Clotilde Bourin, Ping Chen, John F McElroy, John E Leet, David A Stock

Exp Clin Psychopharmacol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Commercially Available Sodium Pentobarbital Formulations on Plasma Hemoglobin Levels in New Zealand White Rabbits.
Vincent J. Guarniere, David G. Schabdach, David A. Stock, Lynn S. Keller

Contemp Top Lab Anim Sci· May 1999

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis